3区 · 医学
Article
作者: Oki, Yasuhiro ; Suh, Cheolwon ; Kim, Jin Seok ; Inman, Shannon ; Gunter, Kurt C ; Combs, Katherin E ; Yoon, Dok Hyun ; Murray, Maryann ; Ardeshna, Kirit M ; Kim, Seok Jin ; Lee, Hun Ju ; Radford, John ; Jacobsen, Eric D ; Ruan, Jia ; Bollard, Catherine M ; Rooney, Cliona M ; Bachy, Emmanuel ; Kang, Hye Jin ; Porcu, Pierluigi ; Suarez, Felipe ; Yoon, Sang Eun ; Budde, Lihua E ; Lee, Daniel Y ; Advani, Ranjana ; Jaccard, Arnaud ; Brammer, Jonathan E ; Lin, Yi ; Heslop, Helen E ; Kim, Won Seog
We conducted a phase II clinical trial to develop an autologous EBV-specific T cell product (baltaleucel T) for advanced, relapsed ENKTL. Among 47 patients who provided whole blood starting material for manufacturing the product, 15 patients received a median of 4 doses of baltaleucel T. Thirty-two (68%) patients did not receive baltaleucel-T due to manufacturing failure, rapid disease progression, and death. Of the 15 patients, 10 patients had measurable disease at baseline (salvage cohort), and 5 patients had no disease at baseline assessment (adjuvant cohort). In the 15 patients, the median follow-up duration was 10.2 months (range 2.0-23.5 months), median progression-free survival (PFS) was 3.9 months, and the median overall survival (OS) was not reached. Patients in the salvage cohort achieved a 30% complete response (CR) and a 50% overall response rate (ORR). In the adjuvant cohort, disease progression was reported in three patients and two patients did not relapse during study follow-up. When we compared survival outcomes of seven responders and eight non-responders, the PFS (P = 0.001) and OS (P = 0.014) of responders proved statistically superior to that of non-responders. Baltaleucel-T was well tolerated. We have performed a phase II clinical trial of autologous EBV-specific T cell treatment (baltaleucel-T) in R/R ENKTL. Autologous EBV-specific T cells were well tolerated and demonstrated single-agent activity in R/R ENTKL.